Related Experiment Videos

Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor

M C Francis1, J J Frohlich

  • 1Department of Pathology and Laboratory Medicine, Healthy Heart Program, University of British Columbia, St. Paul's Hospital, 180-1081 Burrard St., BC, V6Z 1Y6, Vancouver, Canada.

Atherosclerosis
|February 27, 2001
PubMed

Insights

Apolipoprotein-AI (apoAI) may be an independent risk factor for coronary artery disease (CAD) in low-risk individuals. Lower apoAI levels were linked to CAD, even without major risk factors, suggesting a role in atherosclerosis.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Epidemiology

Background:

  • Established coronary artery disease (CAD) risk factors do not explain all cases.
  • Preliminary findings suggest apolipoprotein-AI (apoAI) may be lower in patients with CAD despite lacking major risk factors.

Purpose of the Study:

  • To investigate if apolipoprotein-AI (apoAI) is an independent risk factor for CAD in low-risk populations.
  • To determine the predictive value of apoAI for CAD in individuals without traditional risk factors.

Main Methods:

  • 1075 consecutive patients undergoing angiography were analyzed.
  • A subgroup of 54 low-risk patients (defined by cholesterol, blood pressure, diabetes, and family history) were selected.
  • Multivariate analysis was performed on lipid profiles, including apoAI and HDL cholesterol.

Main Results:

  • Serum apoAI level was the sole predictor of CAD in low-risk patients after adjusting for age and gender.
  • This association was independent of high-density lipoprotein (HDL) cholesterol levels and its fractional esterification rate (FER(HDL)).
  • 29 out of 54 low-risk patients had evidence of CAD, with lower apoAI levels.

Conclusions:

  • Apolipoprotein-AI (apoAI) plays a significant role in the atherogenic process, particularly in individuals without major CAD risk factors.
  • Decreased apoAI or LpAI levels may initiate atherosclerosis in a select group of low-risk patients.
  • apoAI represents a potential novel biomarker for CAD risk assessment in specific populations.

Related Concept Videos